Aphria Inc (TSX:APHA) Gets the Green Light for Expansion: Should You Buy the Stock?

Aphria Inc (TSX:APHA)(NYSE:APHA has received approval from Health Canada to go ahead with its planned expansion. Time to buy?

If any Canadian marijuana producer has had a wild ride over the past year, it would have to be Aphria (TSX:APHA)(NYSE:APHA). After a fourth quarter of 2018 that included short attacks, lawsuits, and a hostile takeover bid, the company entered 2019 with a major management shakeup that fundamentally transformed the company.

For months afterward, it was all quiet on the Aphria front. But now, the company is back in the news with an announcement that it has received clearance from Health Canada to pursue a major expansion project. This news is a signal that Aphria could be gearing up for even more growth after increasing revenue 154% year over year in its most recent quarter. To understand why this news is so big, we need to take a look at what exactly Health Canada approved.

Health Canada approves expansion

For marijuana growers, nothing is more important than production space. The ability to meet the growing demand for cannabis in this country requires significant grow space, and so far, the cannabis growers don’t have enough of it. As a result, the post legalization era has been marked by major supply shortages.

For Aphria, that may be about to change. Earlier this month, Health Canada approved an 800,000-square-foot expansion to the Aphria One grow space in Leamington. This new space will have the capacity to produce 110,000 kg of marijuana a year for about $800 million in revenue at the current cannabis selling price.

$1 billion in revenue predicted

Partially as a result of the recent expansion, Aphria is now forecasting $1 billion in revenue by the end of 2020. The math behind this makes sense given the figures above: the space the company is adding will be able to generate $800 million a year, and that’s on top of the company’s existing space, which drove about $13 million in sales in the most recent quarter. This would represent phenomenal revenue growth, the only question being whether demand for cannabis will be strong enough to justify it.

Takeover seems unlikely

A final point about Aphria is worth mentioning — this one pertaining to the much-discussed hostile takeover bid from Green Growth Brands.

Thanks to all the good news coming from Aphria, it seems unlikely that the Green Growth bid will go through. The all-stock bid valued Aphria at about $9, but with the company’s meteoric growth, its stock has risen to $13 so far this year. Assuming this price level holds, Aphria will be well out of Green Growth’s reach. This is good news for Aphria shareholders, since it means they won’t be forced to exchange each of their shares for 1.5 shares in a much less proven enterprise. This, combined with the recently approved expansion, indicates that this once maligned company may have a bright future ahead of it.

Fool contributor Andrew Button has no position in any of the stocks mentioned.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »